Abstract
With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Protein & Peptide Letters
Title: Radiolabeled Peptides and Proteins in Cancer Therapy
Volume: 14 Issue: 3
Author(s): Carmen Wangler, Inga Buchmann, Michael Eisenhut, Uwe Haberkorn and Walter Mier
Affiliation:
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Abstract: With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Export Options
About this article
Cite this article as:
Wangler Carmen, Buchmann Inga, Eisenhut Michael, Haberkorn Uwe and Mier Walter, Radiolabeled Peptides and Proteins in Cancer Therapy, Protein & Peptide Letters 2007; 14 (3) . https://dx.doi.org/10.2174/092986607780090874
DOI https://dx.doi.org/10.2174/092986607780090874 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Subject Index to Volume 7
Combinatorial Chemistry & High Throughput Screening Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Current and Future Applications of Probiotics
Current Nutrition & Food Science 1, 25(OH)<sub>2</sub>D<sub>3</sub> Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes
Current Medicinal Chemistry Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Application of Optimization Technique to Develop Nano-Based Carrier of Nigella Sativa Essential Oil: Characterization and Assessment
Recent Patents on Drug Delivery & Formulation Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents
Current Drug Targets Synthesis and Cytotoxicities of 2-[4-hydroxy-(3,5-bis-aminomethyl)- benzylidene]-indan-1-ones
Letters in Drug Design & Discovery Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Overview of Genomic Insights into Chicken Growth Traits Based on Genome- Wide Association Study and microRNA Regulation
Current Genomics Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science